SK Biopharmaceuticals (326030) Stock Outlook 2026: XCOPRI Revenue Ramp and the CNS Pipeline Bet
SK Biopharmaceuticals (KOSPI 326030) 2026 outlook: XCOPRI (cenobamate) US prescription growth, direct-sales model economics, CNS pipeline depth, competitive position in epilepsy treatment, and what foreign investors need to know before buying a Korean biotech.
326030 SKBiopharmaceuticals KoreaStocks